|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Inovio Pharmaceuticals, Inc.
| | | Phone: | (858) 597-6006 | Fax: | (858) 597-0451 | Year Established: | 1983 | Ticker: | INO | Exchange: | NYSE | Main Contact: | Niranjan Y. Sardesai, Ph.D., COO | | Other Contacts: | Mark Bagarazzi, MD, CMO Peter Kies, CFO J. Joseph Kim, Ph.D., President & CEO Mark Twyman, VP, Commercial Laurent Humeau, Ph.D., Senior VP, R&D & CSO Peter Kies, CFO
| | Company Description | Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines are designed to provide universal cross-strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with Inovio's proprietary electroporation delivery, have been shown in humans to generate best-in-class immune responses with a favorable safety profile. Inovio's clinical programs include phase II studies for cervical dysplasia, leukemia and hepatitis C virus and phase I studies for influenza and HIV. Partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, US Dept. of Homeland Security and PATH Malaria Vaccine Initiative. | |
|
|
|
|
|